Key result
Ischemia-modified albumin levels were significantly higher in patients with acute coronary syndrome and acute ischemic stroke compared to controls (p<0.001), demonstrating diagnostic sensitivities of 83% and 87%, respectively.
Why the study?
Does ischemia-modified albumin (IMA) measurement provide diagnostic value for acute coronary syndrome and acute ischemic stroke in the emergency department?
Case-Control (n=90)
No
Does ischemia-modified albumin (IMA) measurement provide diagnostic value for acute coronary syndrome and acute ischemic stroke in the emergency department?
Ischemia-modified albumin (IMA) demonstrates high sensitivity and specificity, suggesting it could be a useful early diagnostic biomarker for acute coronary syndrome and acute ischemic stroke in the emergency department.
Answers are grounded in this paper and cite their sources.
IMA elevation associated with ACS and AIS; leaves open diagnostic utility pending prospective validation.
OBJECTIVE: To investigate diagnostic value of ischemia-modified albumin (IMA) levels in patients applying to emergency with symptoms of acute coronary syndrome (ACS) and acute ischemic stroke (AIS). METHODS: Two patient groups (ACS and AIS) and a control group were constituted. The study was discontinued upon reaching 30 patients in each group. Following patient approval at the initial visit, a total of 10 ml venous blood sample was obtained from all patients with a high clinical suspicion of ACS and AIS. The Troponin I and the IMA levels were determined in the blood samples. RESULTS: Statistically significant higher IMA values were determined in the patient groups compared to the control group (p<0.001 for both groups). No statistically significant correlation was found between the IMA and the Troponin I values in the ACS and the AIS groups (p>0.05 for both groups). The sensitivity of IMA was 83% and 87% for ACS and AIS, respectively. The specificity of IMA was 90% and 87% for ACS and AIS, respectively. CONCLUSION: The sensitivity and specificity values, determined according to the optimal cut-off values in the groups demonstrated that IMA could be a useful diagnostic marker in ACS and AIS patients.
No takes yet. Share an insight, caveat, or question.
Ertekin et al. (2013) conducted a case-control in Acute coronary syndrome and acute ischemic stroke (n=90). Ischemia-modified albumin (IMA) levels vs. Control group without thromboembolism or hypoxic-ischemic disturbances was evaluated on Ischemia-modified albumin (IMA) levels (p=<0.001). Ischemia-modified albumin levels were significantly higher in patients with acute coronary syndrome and acute ischemic stroke compared to controls (p<0.001), demonstrating diagnostic sensitivities of 83% and 87%, respectively.
Synapse has enriched 10 related papers. Consider them for comparative context: